TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00510614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole
Description: 1 gram twice weekly for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one pill twice weekly for 12 weeks
Study: NCT01645150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Description: 12 weeks of supervised progressive strength training
Study: NCT02819570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V cefuroxime 750 mg*3/d for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V ampicillin 2 gram x4/d for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P.O cefuroxime 500 mgx2/d for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P.O roxithromycin 150 mg*2/d for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P.O roxithromycin 150 mg*2/d for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P.O moxypen 500 mgx3/d for 5 days
Study: NCT03606564

Intervention type: OTHER
Intervention: study of fasting time among pediatric patients undergoing day care surgery
Description: parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
Study: NCT02329847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
Study: NCT04940975

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Insomnia Education Program at Integrated Mental Health Clinic (IMHC)
Description: A program composed of four educational sessions on sleep and insomnia, plus relaxation training, plus two individual review sessions on sleep hygiene with participant.
Study: NCT01498887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720)
Description: Hard gelatin capsules containing 0.5 mg of fingolimod.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720)
Description: Hard gelatin capsules containing 0.5 mg of fingolimod.
Study: NCT01151852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
Study: NCT01951352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soap
Study: NCT00616902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol injection 4 mcg/mL
Description: Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 4 mcg/mL
Description: Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
Study: NCT02329847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
Study: NCT02749344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FET after endometrial preparation
Description: Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
Study: NCT03225287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan (RA101495)
Description: Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
Study: NCT02028598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Description: An oral single dose administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 3
Description: Co-administration of oral single doses
Study: NCT01562977

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab, Gemcitabine, Oxaliplatin, Dexametasone
Description: until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
Study: NCT04125979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In minimally invasive surgery，Vagus nerve preservation
Description: In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In minimally invasive surgery，Vagus nerve is not preserved
Description: In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
Study: NCT00713804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Booklet
Description: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
Study: NCT01414998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball vs Nicotine-free E-Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Ball vs Nicotine-free E-Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~2. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nicotine-free E-Cigarette vs De-nicotinised Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine-free E-Cigarette vs De-nicotinised Cigarette
Description: In a cross over design, participants will be randomly allocated to:~1. use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~2. smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm.
Study: NCT03044314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost and nitric oxide administration
Description: Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
Study: NCT02923765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training by a stepper
Description: Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
Study: NCT00449163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT00606307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: 50 mg b.i.d. PO every day. More precisely, ITF2357 was supplied as 50 mg hard gelatine capsules for oral administration.
Study: NCT01690182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study test meal 1
Description: Volunteers will be fed with a high volume, high energy density test meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study test meal 2
Description: Volunteers will be fed with a high volume, low energy density test meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study test meal 3
Description: Volunteers will be fed with a low volume, high energy density test meal
Study: NCT03512522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Group
Description: An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workbook Group
Description: An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
Study: NCT01102309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot therapy (NeReBot)
Description: Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
Study: NCT03781726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir/pibrentasvir treatment
Description: combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
Study: NCT04347408

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 Antibody testing (IgG and IgM)
Description: Antibody testing for previous exposure to Covid-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 Antibody testing (IgG and IgM)
Description: Antibody testing for previous exposure to Covid-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 Antibody testing (IgG and IgM)
Description: Antibody testing for previous exposure to Covid-19

Intervention type: OTHER
Intervention: Blood Storage
Description: Storage of blood for multi-omics analysis

Intervention type: OTHER
Intervention: Blood Storage
Description: Storage of blood for multi-omics analysis

Intervention type: OTHER
Intervention: Blood Storage
Description: Storage of blood for multi-omics analysis
Study: NCT01107925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Administered orally, daily for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: Administered orally, daily for 12 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Administered orally, daily for 12 days
Study: NCT00569452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Spirit Insulin Pump
Description: One basal rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Spirit Insulin Pump
Description: Multiple basal rates
Study: NCT03765606

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Flavanol beverage mix
Description: Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: De-xanthinated Cocoa Flavanol beverage mix
Description: Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
Study: NCT01677741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
Study: NCT04241549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
Study: NCT02807935

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical coherence tomography imaging
Study: NCT04241549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
Study: NCT02852460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid recovery
Study: NCT03718429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg Tablet
Description: PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg Tablet
Description: PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg Tablet
Description: PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
Study: NCT03641508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
Study: NCT03279809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Case with placebo medication for 6 months after stenting
Study: NCT03658551

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein
Description: Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein
Description: Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
Study: NCT00545025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection
Study: NCT03883243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecoaching
Description: A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
Study: NCT04301856

Intervention type: DRUG
Intervention: CFTR Modulators
Description: CFTR modulators as recommended in routine care by the french health authorities
Study: NCT03908788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intplex test
Description: Blood sample at each tumor assessment